At Lonza we always welcome interest and inquiries from the media about our business, services and capabilities. Please use the resources on this page, or contact our media relations team for specific inquiries, and we will connect you to the appropriate business leader or subject matter expert.

29 April 2021
Lonza and Moderna Enter New Agreement to Double Drug Substance Production for...
New agreement for three further production lines at Lonza’s site in Visp, Switzerland Additional production lines will come online sequentially All...
23 June 2021
CellPoint and Lonza to Leverage the Cocoon Platform for T-Cell Therapeutics...
CellPoint and Lonza will collaborate to rapidly develop several T-cell based therapies and utilize the Cocoon® Platform for clinical point-of-care manufacturing The goal is to...
06 May 2021
Lonza Announces Results of the 2021 Annual General Meeting – All Motions...
47,080,080 shareholders delegated their votes to the independent proxy, representing 63.22% of the share capital Shareholders re-elected all existing members of the Board of...